Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$2.11 USD
+0.34 (19.21%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $2.10 -0.01 (-0.47%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Mersana Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 209 | 281 | 178 | 255 | 100 |
Receivables | 0 | 30 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 9 | 11 | 3 | 2 |
Total Current Assets | 214 | 319 | 189 | 259 | 101 |
Net Property & Equipment | 4 | 4 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 1 | 2 | 2 | 1 |
Total Assets | 226 | 334 | 206 | 273 | 108 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 14 | 12 | 8 | 7 |
Current Portion Long-Term Debt | 2 | 0 | 0 | 0 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 22 | 43 | 29 | 16 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 29 | 32 | 4 | 4 | 5 |
Total Current Liabilities | 64 | 92 | 48 | 30 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 97 | 117 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 23 | 25 | 25 | 5 | 4 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 1 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 189 | 242 | 84 | 45 | 29 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 863 | 747 | 572 | 509 | 271 |
Retained Earnings | -826 | -655 | -450 | -280 | -192 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 37 | 92 | 122 | 228 | 78 |
Total Liabilities & Shareholder's Equity | 226 | 334 | 206 | 273 | 108 |
Total Common Equity | 37 | 92 | 122 | 228 | 78 |
Shares Outstanding | 120.70 | 99.70 | 71.90 | 68.50 | 47.80 |
Book Value Per Share | 0.31 | 0.92 | 1.69 | 3.33 | 1.64 |
Fiscal Year End for Mersana Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 163 | 183 | 209 | 241 | 287 |
Receivables | 2 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 4 | 5 | 9 | 11 |
Total Current Assets | 169 | 188 | 214 | 250 | 297 |
Net Property & Equipment | 3 | 3 | 4 | 4 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 0 | 0 | 0 | 1 |
Total Assets | 179 | 198 | 226 | 263 | 311 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 3 | 7 | 13 | 17 |
Current Portion Long-Term Debt | 8 | 5 | 2 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 18 | 16 | 22 | 29 | 33 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 29 | 26 | 29 | 23 | 22 |
Total Current Liabilities | 62 | 53 | 64 | 68 | 75 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 88 | 92 | 97 | 112 | 114 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 17 | 20 | 23 | 25 | 25 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 171 | 170 | 189 | 211 | 221 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 878 | 874 | 863 | 859 | 855 |
Retained Earnings | -870 | -846 | -826 | -807 | -765 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 8 | 28 | 37 | 52 | 90 |
Total Liabilities & Shareholder's Equity | 179 | 198 | 226 | 263 | 311 |
Total Common Equity | 8 | 28 | 37 | 52 | 90 |
Shares Outstanding | 122.30 | 121.30 | 120.70 | 120.50 | 114.30 |
Book Value Per Share | 0.07 | 0.23 | 0.31 | 0.43 | 0.79 |